Compare Arqit Quantum Inc (ARQQ) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arqit Quantum Inc vs BioNTech SE - ADR — how do they compare? Arqit Quantum Inc trades at $23.6 (market cap $424.79M), while BioNTech SE - ADR trades at $92.68 (market cap $23.31B). The key difference: BioNTech SE - ADR is far larger — about 54.9× Arqit Quantum Inc's market cap. Which is the better fit depends on your goals.
| ARQQ | BNTX | |
|---|---|---|
Market Cap | $424.79M | $23.31B |
Sector | Technology | Health |
52-Week High | $58.27 | $119.34 |
52-Week Low | $11.78 | $83.89 |
Enterprise Value | $398.10M | $6.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARQQ trades at $23.70, up 4.82% today, with a bullish technical signal from moving averages and ADX. The stock shows extreme valuation metrics with a P/S of 352.9 and P/B of 14.9, while fundamentals reveal severe losses: Q1 2026 EPS missed at -$1.99, net income margin is -4,508.1%, and revenue remains minimal at $530K for 2025. Recent news highlights a proof of concept with nLighten and 829% YoY revenue growth in H1 FY26, signaling potential commercial traction in quantum-safe encryption.
Outlook hinges on scaling revenue to justify valuation, with risks from persistent cash burn and high SG&A. Analyst sentiment is split 50/50 buy/hold, reflecting optimism for government/telecom contracts against financial distress. The stock faces volatility near resistance at $25, requiring sustained growth to support bullish momentum.
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
